Please assess the completion status of the following clinical trial:

Trial Title: Vitamin D and Vitamin B12 Supplementation With Pegylated Interferon-Alfa Plus Ribavirin for Treating Chronic Hepatitis C

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Genotype 1 HCV infection confirmed a positive test for anti-HCV antibody and detectable serum HCV RNA by PCR~* Pegylated Interferon-Alfa treatment naïve~* Liver biopsy with Metavir F2 or less~* Cognitive capacity to understand and sign the informed consent~Exclusion Criteria:~* HBV or HIV co-infection~* Hemoglobin level less than 10 g/dL or total neutrophil count less than 1,500/mm3 or platlet count below 75,000/mm3~* Creatinin ≥ 1.5 mg/dL~* Severe cardiopathy~* Pregnancy or impossibility to use birth control methods by the couple, or breast-feeding~* Conditions that, according to the investigator's judgement, preclude participation in the study, including clinical, cognitive or behavioural conditions

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Control (Type: NO_INTERVENTION): Pegylated Interferon-Alfa plus ribavirin for 48 weeks
- Vitamins (Type: EXPERIMENTAL): Pegylated Interferon-Alfa plus ribavirin for 48 weeks together oral vitamin D 2,000 IU qd throughout, irrespective of baseline vitamin D level. Intramuscular vitamin B12 5000 UI will be given weekly in the first 12 weeks followed by a monthly injection until the end of therapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).